Renal cisplatin chemoembolization with Angiostat, Gelfoam, and Ethiodol in the rabbit: renal platinum distributions.

Abstract

Renal platinum distributions were determined in rabbits after administration of 0.4 mL of 1 mg/mL cisplatin by intravenous infusion, by injections into the left renal artery with aqueous contrast material and with lipid contrast material (Ethiodol), and by chemoembolization of the left renal artery with concurrent administration of various concentrations of two collagen carriers, Angiostat collagen for embolization and Gelfoam gelatin. Renal platinum concentration was measured in tissue homogenates at 2 1/2 hours with atomic absorption spectrometry. Target-kidney platinum levels were 5.4 and 6.9 times the contralateral-kidney levels after intraarterial infusion of aqueous and lipid contrast media, respectively. With Angiostat and Gelfoam chemoembolization, renal platinum retention and collagen concentration were linearly related (r = .87 and .81, P less than .001). Target-kidney-contralateral-kidney platinum ratios were 57:1 for 30 mg/mL Gelfoam and 220:1 for 10 mg/mL Angiostat. The difference in regional drug retention for Angiostat versus Gelfoam reflects the stable fiber integrity of Angiostat.

Preparation of differently sized injectable collagen micro-scaffolds

“…Injectable collagen particles have been developed for drug delivery (Berthold et al , 1998; Schlapp et al , 2003) or as thrombotic agents (Bartynski et al , 1988; Dumas et al , 1992; Turjman et al , 1995) combined with antibiotics delivery (Sternlicht et al , 1989). However, highly porous micro‐scaffolds prepared from native collagen fibrils for tissue engineering have not been reported.…”

Improved Tumor Targeting by Regional Carboplatin Application Combined with Gelfoam^®

“…The liver is very well suited for regional chemotherapy, since liver tumors are mainly perfused via the hepatic artery, whereas liver parenchyma are mainly perfused via the portal vein. Because of the pharmacokinetic properties, the regional advantage can be further increased by reducing the regional flow rate [5]. The intra-arterial application of embolizing substances in tumor therapy was further developed by Goldstein et al [6] and Goldstein and Wallace [7], with the aim of inducing ischemic lesions in tumor tissue.…”

“…Chemoembolization with carboplatin has not yet been tested clinically or experimentally. In this study, absorbable gelatine powder (Gelfoam ® ), which has been applied in a large number of experimental and clinical studies [2,5,10,[17][18][19], was used as the embolisate.…”